HC Wainwright Reaffirms “Buy” Rating for Aprea Therapeutics (NASDAQ:APRE)

HC Wainwright reaffirmed their buy rating on shares of Aprea Therapeutics (NASDAQ:APRE) in a research note issued to investors on Thursday, Benzinga reports. HC Wainwright currently has a $20.00 price target on the stock.

Separately, Wedbush reiterated an “outperform” rating and issued a $11.00 price objective on shares of Aprea Therapeutics in a research note on Tuesday, August 13th.

Aprea Therapeutics Stock Performance

Shares of APRE stock opened at $4.08 on Thursday. The stock has a market capitalization of $22.15 million, a P/E ratio of -1.23 and a beta of 1.03. Aprea Therapeutics has a fifty-two week low of $2.15 and a fifty-two week high of $8.85. The company has a 50 day moving average price of $3.27 and a 200 day moving average price of $4.07.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.05. Aprea Therapeutics had a negative net margin of 1,012.37% and a negative return on equity of 56.38%. The business had revenue of $0.56 million during the quarter, compared to the consensus estimate of $0.10 million. On average, research analysts forecast that Aprea Therapeutics will post -2.74 EPS for the current fiscal year.

Insider Buying and Selling at Aprea Therapeutics

In other Aprea Therapeutics news, Director Bernd R. Seizinger bought 10,000 shares of the stock in a transaction dated Friday, October 11th. The stock was bought at an average cost of $2.68 per share, for a total transaction of $26,800.00. Following the completion of the purchase, the director now directly owns 44,730 shares of the company’s stock, valued at approximately $119,876.40. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Aprea Therapeutics news, Director Marc Duey sold 6,462 shares of the business’s stock in a transaction on Friday, October 18th. The stock was sold at an average price of $4.58, for a total transaction of $29,595.96. Following the completion of the transaction, the director now owns 233,651 shares in the company, valued at approximately $1,070,121.58. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Bernd R. Seizinger acquired 10,000 shares of the company’s stock in a transaction dated Friday, October 11th. The stock was purchased at an average cost of $2.68 per share, for a total transaction of $26,800.00. Following the purchase, the director now directly owns 44,730 shares in the company, valued at approximately $119,876.40. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 42,290 shares of company stock valued at $165,096 over the last ninety days. Corporate insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Stonepine Capital Management LLC bought a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics comprises approximately 0.5% of Stonepine Capital Management LLC’s portfolio, making the stock its 21st biggest holding. Stonepine Capital Management LLC owned about 2.53% of Aprea Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.